La catena delle opzioni mostra i dati chiave delle opzioni azionarie di DocGo a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per DocGo..

DocGo (NASDAQ:DCGO) Azioni, Catena delle Opzioni

DocGo

DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company has three reportable segments: Mobile Health Services, Transportation Services, and Corporate. Mobile Health Services is the key revenue-generating segment for the company.

DocGo Inc

Beyond Meat Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) reported third-quarter financial results Wednesday after the bell. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/11/g41786618/beyond-meat-reports-third-quarter-2024-financial-results">rundown of the report</a>.
Q3 Earnings: Beyond Meat reported third-quarter revenue of $81.01 million, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $80.71 million, according to&nbsp;<a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.&nbsp;The&nbsp;plant-based meat&nbsp;company reported a third-quarter adjusted loss of 41 cents per share, beating estimates for a loss of 44 cents per share.
Total revenues increased 7.6% on a year-over-year basis. U.S. retail channel net revenues increased&nbsp;14.6% year-over-year and U.S. foodservice channel net revenues increased&nbsp;15.5%. International retail channel net revenues jumped 17% year-over-year while international foodservice channel net revenues fell 17.2%.
Beyond Meat ended the quarter with $134.9 million in cash, cash equivalents and restricted cash. The company had total outstanding debt of $1.1 billion as of Sept. 28.
&#8220;We are pleased to report that in the third quarter, we returned to growth, increasing net revenues on a year-over-year basis, while continuing to expand gross margin and reduce operating expenses on both a sequential and year-over-year basis,&#8221; said Ethan Brown, president and CEO of Beyond Meat.
&#8220;Looking ahead, we expect to increase our cash reserves by year-end and pursue further balance sheet restructuring in 2025.&#8221;
Outlook:&nbsp;Beyond Meat revised its full-year 2024 revenue outlook from a range of $320 million to $340 million to a new range of $320 million to $330 million. Analysts are anticipating full-year revenue of $328.59 million, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Management will further discuss the company&#8217;s quarterly results on a conference call slated for 5 p.m. ET.
BYND Price Action: <a href="https://www.benzinga.com/quote/BYND" target="_blank" rel="noreferrer noopener">Beyond Meat shares</a> were down 5.78% after hours at $6.20 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Don&#8217;t Miss: • <a href="https://www.benzinga.com/general/politics/24/11/41745522/trump-or-harris-as-mcdonalds-managers-benzinga-readers-would-rather-have-this-candidate-as-their">Trump Or Harris As McDonald&#8217;s Managers? Benzinga Readers Would Rather Have This Candidate As Their Boss At The Restaurant</a>
Photo: Courtesy of Beyond Meat.

Earnings

News

Guidance

Movers

BYND

Beyond Meat Returns To Growth In Q3: Revenue Beat, EPS Beat, Cash Reserves In Focus

F&amp;G Annuities &amp; Life (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FG#NYSE">FG</a>) reported quarterly earnings of $1.22 per share which beat the analyst consensus estimate of $1.09 by 11.93 percent. The company reported quarterly sales of $2.39 billion which beat the analyst consensus estimate of $1.22 billion by 95.09 percent. This is a 180.38 percent increase over sales of $851.00 million the same period last year.

Earnings Beats

F&G Annuities & Life Q3 2024 Adj EPS $1.22 Beats $1.09 Estimate, Sales $2.39B Beat $1.22B Estimate

Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.30) by 63.33 percent. The company reported quarterly sales of $2.326 billion which missed the analyst consensus estimate of $2.697 billion by 13.76 percent. This is a 10.19 percent decrease over sales of $2.590 billion the same period last year.

Earnings Misses

CTVA

Corteva Q3 2024 Adj. EPS $(0.49) Misses $(0.30) Estimate, Sales $2.326B Miss $2.697B Estimate

Grand Canyon Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOPE#NASDAQ">LOPE</a>) narrows FY2024 GAAP EPS guidance from $7.63-7.81 to $7.76-7.79 vs $7.73 analyst estimate..

LOPE

Grand Canyon Education Narrows FY2024 GAAP EPS Guidance from $7.63-7.81 to $7.76-7.79 vs $7.73 Est

Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.35) by 2.86 percent. This is a 52.11 percent increase over losses of $(0.71) per share from the same period last year.

ACET

Adicet Bio Q3 EPS $(0.34) Beats $(0.35) Estimate

KVYO

Klaviyo Sees Q4 2024 Revenue $256M-$258M Vs $257.02M Estimate; Sees FY24 Revenue $923M-$925M Vs $915.6M Estimate

WOLF

Wolfspeed Sees Q2 Revenue $160M-$200M Vs $214.583M Est.; Adj. EPS $(1.14)-$(0.89) Vs $(0.90) Est.

Grand Canyon Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOPE#NASDAQ">LOPE</a>) narrows Q4 GAAP EPS guidance from $2.78-2.91 to $2.86-2.89 vs $2.85 analyst estimate..

Grand Canyon Education Narrows Q4 GAAP EPS Guidance from $2.78-2.91 to $2.86-2.89 vs $2.85 Est

ATRO

Astronics Sees FY24 Capital Expenditures $9M-$11M

SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) sees Q4 sales of $180.000 million-200.000 million vs $308.66 million estimate.

SEDG

SolarEdge Technologies Sees Q4 Sales $180.000M-200.000M vs $308.66M Est

Grand Canyon Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOPE#NASDAQ">LOPE</a>) narrows Q4 Adj EPS guidance from $2.84-2.97 to $2.92-2.95 vs $2.91 analyst estimate. Narrows Q4 sales outlook from $286.50 million-291.50 million to $289.00 million-290.00 million vs $289.30 million estimate.

Grand Canyon Education Narrows Q4 Adj EPS Guidance from $2.84-2.97 to $2.92-2.95 vs $2.91 Est; Narrows Q4 Sales Guidance from $286.50M-291.50M to $289.00M-290.00M vs $289.30M Est

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) reported quarterly earnings of $2.14 per share which beat the analyst consensus estimate of $2.12 by 0.94 percent. The company reported quarterly sales of $1.33 billion which met the analyst consensus estimate. This is a 1.04 percent decrease over sales of $1.34 billion the same period last year.

Steris Q2 2025 Sales $1.328B, Miss $1.33B Estimate

Management

NCR Voyex Announced The Appointment Of Darren Wilson as President, International.

NewtekOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWT#NASDAQ">NEWT</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.43 by 4.65 percent. The company reported quarterly sales of $62.832 million which beat the analyst consensus estimate of $61.398 million by 2.34 percent. This is a 23.26 percent increase over sales of $50.974 million the same period last year.

NEWT

NewtekOne Q3 2024 GAAP EPS $0.45 Beats $0.43 Estimate, Sales $62.832M Beat $61.398M Estimate

Astronics Sees FY24 Revenue $777M-$797M Vs $780.835M Est; Sees Q4 Revenue $190M-$210M

2024 OUTLOOK
The Company has maintained its previous midpoint full year comparable hotel guidance, which assumes a continued recovery in Maui and steady demand trends in the fourth quarter, despite the impacts of Hurricanes Helene and Milton. Operating profit margin and comparable hotel EBITDA margins in 2024 are expected to decline compared to 2023, impacted by the Maui wildfires and continued growth in wages, real estate taxes and insurance.
The Company's full year forecast comparable hotel set now includes the operations of The Ritz-Carlton O'ahu, Turtle Bay and 1 Hotel Central Park properties that were acquired in July 2024, and excludes The Don CeSar, which closed on September 25, 2024, as described above. The estimated impact to net income and Adjusted EBITDAre from the loss of business due to the hurricanes for 2024 is approximately $15&nbsp;million.
The impact from Maui operations is expected to be an approximate decline of 150 basis points in RevPAR and 110 basis points in Total RevPAR. When combined with the expected pre-wildfire Maui contribution, the total impact is estimated to be 220 basis points and 180 basis points, respectively. Net of the benefit of the business interruption gains relating to the wildfires received earlier this year, the year-over-year impact from Maui on net income and Adjusted EBITDAre for full year is expected to be a decline of $25 million, and on margins is expected to be a decline of approximately 20 basis points.
The Company anticipates its 2024 operating results as compared to 2023 will be approximately as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1">Current Full Year 2024 Guidance</td>
<td colspan="1">Current Full Year 2024 Guidance Change vs. 2023</td>
<td colspan="1">Previous Full Year 2024 Guidance Midpoint Change vs. 2023</td>
<td>Change in Full Year 2024 Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Comparable hotel Total RevPAR</td>
<td colspan="1">$353</td>
<td>1.2%</td>
<td>1.2%</td>
<td>0 bps</td>
</tr>
<tr>
<td>Comparable hotel RevPAR</td>
<td colspan="1">$215</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0 bps</td>
</tr>
<tr>
<td>Total revenues under GAAP (in millions)</td>
<td colspan="1">$5,637</td>
<td>6.1%</td>
<td>6.8%</td>
<td>(70) bps</td>
</tr>
<tr>
<td>Operating profit margin under GAAP</td>
<td>15.2%</td>
<td colspan="1">(40) bps</td>
<td colspan="1">0 bps</td>
<td>(40) bps</td>
</tr>
<tr>
<td>Comparable hotel EBITDA margin</td>
<td>29.0%</td>
<td colspan="1">(90) bps</td>
<td colspan="1">(90) bps</td>
<td>0 bps</td>
</tr>
</tbody>
</table>
</figure>
Based upon the above parameters, the Company estimates its 2024 guidance will be approximately as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1">Current Full Year 2024 Guidance</td>
<td colspan="1">Previous Full Year 2024 Guidance Midpoint</td>
<td colspan="1">Change in Full Year 2024 Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Net income (in millions)</td>
<td colspan="1">$687</td>
<td colspan="1">$712</td>
<td colspan="1">$(25)</td>
</tr>
<tr>
<td>Adjusted EBITDAre (in millions)</td>
<td colspan="1">$1,630</td>
<td colspan="1">$1,645</td>
<td colspan="1">$(15)</td>
</tr>
<tr>
<td>Diluted earnings per common share</td>
<td colspan="1">$0.96</td>
<td colspan="1">$0.99</td>
<td colspan="1">$(0.03)</td>
</tr>
<tr>
<td>NAREIT and Adjusted FFO per diluted share</td>
<td colspan="1">$1.92</td>
<td colspan="1">$1.94</td>
<td colspan="1">$(0.02)</td>
</tr>
</tbody>
</table>
</figure>
See the 2024 Forecast Schedules and the Notes to Financial Information for items that may affect forecast results.

Host Hotels & Resorts Sees FY24 Adj. FFO Per Share $192-$1.94; Diluted EPS $0.96-$0.99 Vs $0.95 Est.; Revenue $5.637B Vs $5.62B Est.

Everus Construction Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECG#NYSE">ECG</a>) reported quarterly earnings of $0.82 per share. This is a 15.49 percent increase over earnings of $0.71 per share from the same period last year. The company reported $761.00 million in sales this quarter. This is a 6.08 percent increase over sales of $717.40 million the same period last year.

Everus Construction Group Q3 EPS $0.82 Up From $0.71 YoY, Sales $761.00M Up From $717.40M YoY

Deluxe Sees FY24 Revenue $2.12B-$2.14B Vs $2.135B Est.; Adj. EPS $3.20-$3.35 Vs $3.15 Est.

Ormat Technologies Sees FY24 Revenue $875M-$893M Vs $892.19M Est.

Pennant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNTG#NASDAQ">PNTG</a>) raises FY2024 Adj EPS guidance from $0.89-0.95 to $0.90-0.96 vs $0.91 analyst estimate. Raises FY2024 sales outlook from $654.00 million-694.50 million to $665.30 million-706.50 million vs $679.26 million estimate.

PNTG

Pennant Gr Raises FY2024 Adj EPS Guidance from $0.89-0.95 to $0.90-0.96 vs $0.91 Est; Raises FY2024 Sales Guidance from $654.00M-694.50M to $665.30M-706.50M vs $679.26M Est

DocGo Inc. (DCGO) Q2 2024 Earnings Call Transcript

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Curaleaf Holdings (CURLF – Research Report) and DocG...

Analysts Offer Insights on Healthcare Companies: Curaleaf Holdings (OtherCURLF) and DocGo (DCGO)

Canaccord Genuity analyst Richard Close has maintained their bullish stance on DCGO stock, giving a Buy rating today. Richard Close has given his B...

Buy Rating Affirmed for DocGo on Strong Quarterly Performance and Positive Growth Trajectory

DocGo (DCGO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on August 7. Analyst Pito Chickering from Deu...

DocGo: A Strong Buy on Robust Financial Performance and Growth Prospects

Northland Securities analyst Michael Latimore maintained a Buy rating on DocGo (DCGO – Research Report) today and set a price target of $8.00. The ...

Northland Securities Sticks to Its Buy Rating for DocGo (DCGO)

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 8/26/2024, According to Top Analysts

The latest announcement is out from DocGo ( ($DCGO) ). DocGo Inc. has announced the appointment of Dr. Stephen K. Klasko as the new Chair of its Bo...

DocGo Appoints Dr. Stephen Klasko as New Board Chair

DocGo appoints Stephen Klasko as chair

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on DocGo (DCGO – Research Report), Avidity Biosciences ...

Analysts' Top Healthcare Picks: DocGo (DCGO), Avidity Biosciences (RNA)

Ambulnz by DocGo and Bayhealth renew partnership, extending contract for three years

CURLF

DCGO

OPRA

RARE

Press Releases

DocGo Launches Mobile X-Ray Program in Partnership with MinXray

DocGo Announces Strong Second Quarter 2024 Results

DocGo Announces Participation at Four Upcoming Investor Conferences

DocGo Expands Care Gap Closure Program to Enhance Healthcare Access for Hundreds of Thousands of Medicaid Recipients in California

DocGo Named Finalist for National Compliance Awards

DocGo Appoints Eiwe Lingefors as New Chief Information Officer

DocGo Appoints Healthcare Visionary Dr. Stephen K. Klasko as Chair of the Board

Ambulnz by DocGo and Bayhealth Renew Partnership in Delaware, Extending Contract for Three Years

DocGo to Announce Third Quarter 2024 Results on Thursday, November 7, 2024

Kuehn Law Encourages Investors of DocGo, Inc. to Contact Law Firm

Accolade

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

Castle Biosciences

Enhabit

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Fulgent Genetics

InnovAge Holding

23andMe Holding

ModivCare

National Research Corporation - Common Stock

National Research

Nutex Health

OPKO Health

Performant Financial Corporation - Common Stock

Performant Finl

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Pennant Gr

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

SBC Medical Group Holdings Incorporated - Common Stock

SBC Medical Group Holding

SHL Telemedicine Ltd - American Depositary Shares

Comments

DocGo

DocGo (DCGO) Opzioni

DocGo (NASDAQ:DCGO) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO